Last reviewed · How we verify
Decadron
At a glance
| Generic name | Decadron |
|---|---|
| Also known as | Maxidex, Ozurdex, Baycadron, dexamethasone, Dexamethasone |
| Sponsor | University of Miami |
| Target | Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Weight gain
- Increased appetite
- Nausea
- Headache
- Increased sweating
- Sodium retention
- Fluid retention
- Potassium loss
- Hypertension
- Muscle weakness
- Abdominal distention
- Impaired wound healing
Serious adverse events
- Myocardial rupture following recent myocardial infarction
- Congestive heart failure in susceptible patients
- Perforation of the small and large bowel
- Peptic ulcer with possible perforation and hemorrhage
- Pancreatitis
- Aseptic necrosis of femoral and humeral heads
- Convulsions
- Increased intracranial pressure with papilledema (pseudotumor cerebri)
- Thromboembolism
- Posterior subcapsular cataracts
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Dose Dependent Steroid Injections (PHASE4)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Decadron CI brief — competitive landscape report
- Decadron updates RSS · CI watch RSS
- University of Miami portfolio CI